Neoadjuvant camrelizumab plus nab-paclitaxel and S1 is safe, feasible and effective in locally advanced ESCC and is worth further investigation.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2021) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: